Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 14/20 | 0.80 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18969864 | 1.00 | SPHK1 (0.80) | SPHK1SPHK2L3MBTL1THRATHRB | |
| SCHEMBL18969861 | 1.00 | SPHK1 (0.80) | SPHK1SPHK2L3MBTL1THRATHRB | |
| SCHEMBL11996054 | 1.00 | SPHK1 (0.80) | SPHK1SPHK2L3MBTL1THRATHRB | |
| SCHEMBL18025375 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL11996034 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL11996040 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL11996042 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL11996038 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL11996036 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 | |
| SCHEMBL16945694 | 0.89 | SPHK1 (1.00) | SPHK1SPHK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421177-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885SPHK2 1/4885L3MBTL1 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.